Results 91 to 100 of about 220,753 (136)

Social media activities to enhance the visibility of long-term invasive ventilation: A content and visibility analysis from the PRiVENT study

PLoS ONE
Franziska C. Trudzinski, Nicola Litke, Olaf Buntemeyer, Simone Janssen, Elena Biehler, Thomas Fleischhauer, Jana C. Dahlhoff, Philipp Höger, Axel Kempa, Benjamin Neetz, Biljana Joves, Claus Neurohr, Alessandro Ghiani, Armin Schneider, Joachim Szecsenyi, Jan Meis, Janina Schubert-Haack, Julia D. Michels-Zetsche, Felix JF Herth   +18 more
doaj  

Author response to Comment on: Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database. [PDF]

Ther Adv Neurol Disord
Shirani A, Cross AH, Stuve O.
europepmc   +1 more source

Applying two approaches to detect unmeasured confounding due to time-varying variables in a self-controlled risk interval design evaluating COVID-19 vaccine safety signals, using myocarditis as a case example. [PDF]

Am J Epidemiol
Bots SH, Belitser S, Groenwold RHH, Durán CE, Riera-Arnau J, Schultze A, Messina D, Segundo E, Douglas I, Carreras JJ, Garcia-Poza P, Gini R, Huerta C, Martín-Pérez M, Martin I, Paoletti O, Bissacco CA, Correcher-Martínez E, Souverein P, Urchueguía-Fornes A, Villalobos F, Sturkenboom MCJM, Klungel OH.   +22 more
europepmc   +1 more source

Genetic contribution to severe COVID-19 in adults under 60 years without major comorbidities in the German National Pandemic Cohort Network (NAPKON). [PDF]

Hum Genomics
Abolhassani A, Alawathurage TM, Schmidt A, Brand F, Kilarski LL, Altmann H, Dahl E, Frank S, Göpel S, Hanses F, Hellmuth JC, Herr C, Kaasch AJ, Kobbe R, Konik MJ, Pink I, Römmele C, Rupp J, Scheer CS, Schneider MA, Stellbrink C, Stubbe HC, Tepasse PR, Teufel A, Vadász I, Vehreschild MJGT, Witzenrath M, Anton G, Bröhl I, Herold S, Illig T, Jiru-Hillmann S, Krawitz P, Mitrov L, Philipsen A, Pütz SM, Noethen MM, Nuernberg P, Reese JP, Riess O, Schreiber S, Schultze J, Steinbeis F, Vehreschild JJ, Wildberg C, Ludwig KU, Schulte EC.   +46 more
europepmc   +1 more source

Thigh Injections of Cabotegravir + Rilpivirine in Virally Suppressed Adults With HIV-1: A Substudy of the Phase 3b ATLAS-2M Study. [PDF]

Clin Infect Dis
Ford SL, Felizarta F, Han K, Wang K, Crauwels H, Dari A, Masia M, Garcia Deltoro M, Degen O, Angel JB, Hsiao CB, Acuipil C, Kolobova I, Harrington C, Rimler K, Spreen W, D'Amico R.   +16 more
europepmc   +1 more source

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial. [PDF]

J Clin Oncol
Mai EK, Bertsch U, Pozek E, Fenk R, Besemer B, Hanoun C, Schroers R, von Metzler I, Hänel M, Mann C, Leypoldt LB, Heilmeier B, Huhn S, Vogel SK, Hundemer M, Scheid C, Blau IW, Luntz S, Weinhold N, Tichy D, Holderried TAW, Trautmann-Grill K, Gezer D, Klaiber-Hakimi M, Müller M, Shumilov E, Knauf W, Michel CS, Geer T, Riesenberg H, Lutz C, Raab MS, Benner A, Hoffmann M, Weisel KC, Salwender HJ, Goldschmidt H, German-Speaking Myeloma Multicenter Group (GMMG) HD7 Investigators, German-speaking Myeloma Multicenter Group (GMMG) HD7.   +38 more
europepmc   +1 more source

Tysabri Observational Program (TOP): long-term safety and effectiveness of natalizumab treatment in relapsing-remitting multiple sclerosis over 15 years. [PDF]

J Neurol Neurosurg Psychiatry
Butzkueven H, Kappos L, Wiendl H, Trojano M, Spelman T, Greco A, Sun Z, Lasky T, TOP Investigators.   +8 more
europepmc   +1 more source

The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers. [PDF]

Cancer Res
Federico A, Gopisetty A, Surdez D, Iddir Y, Autry RJ, Waterfall JJ, Saberi-Ansari E, Bobin C, Ballet S, Pierron G, Wierzbinska JA, Schlicker A, Sill M, Volckmann R, Zwijnenburg DA, Mackay A, Zaïdi S, Saint-Charles A, Mack N, Schwalm B, Brabetz S, Weiser L, Buchhalter I, Previti C, Böttcher AL, Iradier F, Rief EM, Jones DTW, Witt O, Westermann F, Milde T, Eggert A, Huebener N, Schulte JH, Colombetti S, Chesler L, Tucker ER, Morcavallo A, Lorenzi F, Kovar H, Klusmann JH, Debatin KM, Bomken S, Guttke CD, Hamerlik P, Hattersley MM, Garcia M, Colland F, Strougo A, Aviles P, Zapotocky M, Sumerauer D, Gojo J, Berger W, Lötsch-Gojo D, Schueler J, Girard EJ, Olson JM, Schäfer BW, Wachtel M, Molenaar JJ, Dumevska B, Fernandez Potente E, Jones C, Carcaboso AM, Indersie E, Cairo S, Scotlandi K, Manara MC, Landuzzi L, Di Giannatale A, Gasparini P, Moro M, Gürgen D, Hoffmann J, Marques da Costa ME, Geoerger B, Delattre O, Shields DJ, Caron HN, Vassal G, Stancato LF, Pfister SM, Jäger N, Koster J, Kool M, Schleiermacher G.   +86 more
europepmc   +1 more source

SUNRISE-CRC: a randomized phase II study of high-dose intermittent sunitinib versus trifluridine/tipiracil in metastatic colorectal carcinoma. [PDF]

Oncologist
Janssen JBE, Iyer KK, Gerritse SL, Janssen E, Gootjes EC, Labots M, Buffart TE, Wumkes ML, Douma JAJ, Streppel MM, Buffart LM, Jonker MA, van den Hombergh E, van Erp NP, Medema JP, Tauriello DVF, Poel D, Verheul HMW.   +17 more
europepmc   +1 more source

Tofacitinib in rheumatoid arthritis: a German real-world study with focus on treatment changes, effectiveness and patient-reported outcomes (ESCALATE-RA). [PDF]

BMJ Open
Krueger K, Behrens F, Brandt-Juergens J, Detert J, Feuchtenberger M, Prothmann U, Behmer O, Hsieh MM, Jobst J, Klaus P, Meng T.   +10 more
europepmc   +1 more source